Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types. (16th October 2015) - Ettlin, R.; Dieterle, W.; Fabbro, D.; Hebeisen, P.; Beaufils, F.; Hillmann, P.; Stumm, M.; Dimitrijević, S.; Wymann, M.; Cmiljanovic, N.; Giese, B.; Cmiljanovic, V.